Role of urokinase plasminogen activator in human breast cancer: Active involvement of stromal fibroblasts

Fibrinolysis

Volumn 10, Issue SUPPL. 2, 1996, Pages 79-83

  Van Roozendaal, C E P ^a   Klijn, J G M ^a   Sieuwerts, A M ^a   Henzen Logmans, S C ^a   Foekens, J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; STROMA;

EID: 0029905948     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80056-7     Document Type: Conference Paper

References (69)

1. Danø K, Andreasen P A, Grøndahl-Hansen J, Kristensen P I, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
2. Liotta L A, Tryggvason K, Garbisa S, Hart I, Foltz C M, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-68.
3. Mignatti P, Rifkin D B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
4. Ellis V, Behrendt N and Danø K. Plasminogen activation by receptor-bound urokinase. J Biol Chem 1991; 266: 12752-2758.
5. Ellis V, Pyke C, Eriksen J, Solberg H and Danø K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 1992; 667: 13-31.
6. Andreasen P A, Georg B, Kund L R, Riccio A, Stacey S N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
7. Duffy M J, O'Grady P, Devaney D, O'Siorain L, Fennelly J J, Lijnen HJ. Urokinase plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 1988; 62: 531-533.
8. Duffy M J, Reilly D, O'Sullivan C, O'Higgins N, Fennelly J J, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-6829.
9. Jänicke F, Schmitt M, Hafter R et al Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78.
10. Foekens J A, Schmitt M, van Putten W L J et al Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-6105.
11. Spyratos F, Martin P M, Hacène K et al Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84: 1266-1272.
12. Grøndahl-Hansen J, Cnristensen I J, Rosenquist C et al High levels of urokinase-type plasminogen activator (u-PA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
13. Foekens J A, Look M P, Peters H A, van Putten W L J, Portengen H, Klijn J G M. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-756.
14. Nekarda H, Schmitt M, Ulm K et al Prognostic impact of urokinase type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-2907.
15. Mulcahy H E, Duffy M J, Gibbons D et al Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344: 583-584.
16. Ganesh S, Sier C F M, Griffioen G et al Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-4071.
17. Kuhn W, Pache L, Schmalfeldt B et al Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994; 55: 401-409.
18. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 1994; 151: 16-20.
19. Ossowski L. In vivo invasion of modified chorioallantoic membranes by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-2445.
20. Ossowski L, Clunie G, Masucci M T, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor invasion. J Cell Biol 1991; 115: 1107-1112.
21. Quax P H A, Pedersen N, Masucci M T et al Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991; 2: 793-803.
22. Kobayashi H, Ohi H, Shinohara M H et al Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 1993; 67: 537-544.
23. Liu G, Shuman M A, Cohen R L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995; 60: 501-506.
24. Holst-Hansen C, Johannessen B, Heyer-Hansen G, Roømer J, Ellis V, Brünner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; in press.
25. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-619.
26. Ossowski L, Russo-Payne H, Wilson E L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-281.
27. Crowley C W, Cohen R L, Lucas B K, Liu G, Shuman M A, Levinson A D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
28. Kobayashi H, Goton J, Fujie M, Shinohara M, Moniwa N, Terao T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within the growth factor-like domain of urokinase in the experimental and spontaneous metastatic model. Int J Cancer 1994; 57: 727-733.
29. Kook Y H, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 17: 3983-3991.
30. Rabbani S A, Harakidas P, Davidson DJ, Henkin J, Mazar A P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (u-PA). Int J Cancer 1995; 63: 840-845.
31. Wolf C, Rouyer N, Lutz Y et al Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993; 90: 1843-1847.
32. Nielsen B S, Sehested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996; 74: 168-177.
33. Setyono-Han B, Klijn J G M, Portengen H, Look M P, Henzen-Logmans SC, Foekens J A. u-PA, u-PA-receptor and PAI-1 expression in human primary breast carcinomas and their matched metastases studied by in situ hybridisation. Proc Am Assoc Cancer Res 1995; 558: 565.
34. Rømer J, Pyke C, Lund L R et al Expression of u-PA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 1994; 57: 553-560.
35. Sappino A-P, Skalli O, Jackson W, Schürch W, Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and nonmalignant breast tissues. Int J Cancer 1988; 41: 707-712.
36. Rønnev-Jessen L, Petersen O W, Koteliansky V E, Bissell M J. The origin of the myofibroblasts in breast cancer: recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95: 859-873.
37. Brouty-Boyé D, Magnien V. Myofibroblast and concurrent ED-B fibronectin phenotype in human stromal cells cultured from nonmalignant and malignant breast tissue. Eur J Cancer 1994; 30A: 66-73.
38. Van Roozendaal C E P, Klijn J G M, van Ooijen B et al Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol 1995; 111: 1-6.
39. Rønnev-Jessen L and Petersen O W. Induction of α-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Lab Invest 1993; 68: 696-707.
40. Pyke C, Græm N, Ralfkiær E et al Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 1911-1915.
41. Bianchi E, Cohen R L, Thor A T et al The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-866.
42. Pyke C, Kristensen P, Ralfkiær E et al Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon cancer. Am J Pathol 1991; 138: 1059-1067.
43. Bassett P, Bellocq J P, Wolf C et al A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
44. Poulsom R, Hanby A M, Pignatelli M et al Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993; 46: 429-436.
45. Okada A, Bellocq J-P, Rouyer N et al Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995; 92: 2730-2734.
46. Grøndahl-Hansen J, Ralfkiær E, Kirkeby L T, Kristensen P, Lund L R, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991; 138: 111-117.
47. De Vries T J, Quax P H A, Denijn M et al Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
48. Wolf C, Chenard M-P, Durand de Grossouvre P, Bellocq J-P, Chambon P, Basset P. Breast-cancer-associated stromelysin 3 in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992; 99: 870-872.
49. Muller D, Wolf C, Abecassis J et al Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993; 53: 165-169.
50. Hewitt R E, Leach I H, Powe D G, Clark I M, Cawston T E, Turner D R. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991; 49: 666-672.
51. Pyke C, Ralfkiær E, Huhtala T, Hurskainen T, Danø K, Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 Type IV collagenases in human skin cancers by in situ hybridisation. Cancer Res 1992; 52: 1336-141.
52. Poulsom R, Pignatelli M, Stetler-Stevenson W G et al Stromal expression of 72 kDa type-IV collagenase (MMP-2) and TTMP-2 messenger RNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-396.
53. Autio-Harmainen H, Kartunen T, Hurskainen T, Höyhtyä M, Kaupilla A Tryggvason K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69: 312-321.
54. Clarke R, Dickson R B, Lippman M E. Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 1992; 12: 1-23.
55. Van den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res 1988; 50: 159-196.
56. Dickson R B, Lippman M E. Growth factors in breast cancer. Endocr Rev 1995; 16: 559-589.
57. Ellis M J C, Singer C, Hornby A, Rasmussen A, Cullen K J. Insulin-like growth factor mediated stromal interactions in human breast cancer. Breast Cancer Res Treat 1994; 31: 249-261.
58. Noël A, dePauw-Gillet M C, Purnell G, Nusgens B, Lapiere C M, Foidart J M. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 1993; 68: 909-915.
59. Horgan K, Jones D L, Mansel R E. Mitogenicity of human fibroblasts in vivo for human breast cancer cells. Br J Surg 1987; 74: 227-229.
60. Mukaida H, Hirabayashi N, Hirai T, Iwata T, Saeki S, Toge T. Significance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth. Int J Cancer 1991; 48: 423-427.
61. Orr D J A, Ryan M C, Horgan K. Demonstration of a positive feedback loop of paracrine growth stimulation in a new co-culture model of breast cancer. Breast 1993; 2: 138-143.
62. Adam L, Crépin M, Lelong J-C, Spanakis E, Isreal L. Selective interactions between mammary epithelial cells and fibroblasts in coculture. Int J Cancer 1994; 59: 262-268.
63. Brouty-Boyé D, Mainguene C, Magnien V, Isreal L, Beaupain R. Fibroblast-mediated differentiation in human breast carcinoma cells (MCF-7) grown as nodules in vitro. Int J Cancer 1994; 56: 731-735.
64. Hofland L J, van der Burg B, van Eijck C H J, Sprij D M, Koetsveld P M, Lamberts S W J. Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide. Int J Cancer 1995; 60: 93-99.
65. Lefebvre M F, Guillot C, Crépin M, Saez S. Influence of tumor derived fibroblasts and 1,25-dihydroxyvitamin D3 on growth of breast cancer cell lines. Breast Cancer Res Treat 1995; 33: 189-197.
66. Adams E F, Newton C J, Braunsberg H, Shaikh N, Ghilchik M, James VH. Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Res Treat 1988; 11: 165-172.
67. Van Roozendaal C E P, van Ooijen B, Klijn J G M et al Stromal influences on breast cancer cell growth. Br J Cancer 1992; 65: 77-81.
68. Van Roozendaal C E P, Klijn J G M, van Ooijen B et al Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer 1996; 65: 120-125.
69. Ryan S, Orr D J, Horgan K. Fibroblast stimulation of breast cancer cell growth in a serum-free system. Br J Cancer 1993; 67: 1268-1273.